Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials.
Flawless balance sheet with solid track record.
Share Price & News
How has Faes Farma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FFEA has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: FFEA exceeded the German Pharmaceuticals industry which returned 17.5% over the past year.
Return vs Market: FFEA exceeded the German Market which returned 12.8% over the past year.
Price Volatility Vs. Market
How volatile is Faes Farma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Faes Farma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FFEA (€4.62) is trading below our estimate of fair value (€8.46)
Significantly Below Fair Value: FFEA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FFEA is good value based on its PE Ratio (21.8x) compared to the Pharmaceuticals industry average (25.6x).
PE vs Market: FFEA is poor value based on its PE Ratio (21.8x) compared to the German market (20.8x).
Price to Earnings Growth Ratio
PEG Ratio: FFEA is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: FFEA is overvalued based on its PB Ratio (3.4x) compared to the DE Pharmaceuticals industry average (2.3x).
How is Faes Farma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FFEA's forecast earnings growth (16.1% per year) is above the savings rate (-0.4%).
Earnings vs Market: FFEA's earnings (16.1% per year) are forecast to grow faster than the German market (13% per year).
High Growth Earnings: FFEA's earnings are forecast to grow, but not significantly.
Revenue vs Market: FFEA's revenue (8.8% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: FFEA's revenue (8.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FFEA's Return on Equity is forecast to be low in 3 years time (17.6%).
How has Faes Farma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FFEA has high quality earnings.
Growing Profit Margin: FFEA's current net profit margins (16.3%) are higher than last year (15%).
Past Earnings Growth Analysis
Earnings Trend: FFEA's earnings have grown by 18.2% per year over the past 5 years.
Accelerating Growth: FFEA's earnings growth over the past year (19.7%) exceeds its 5-year average (18.2% per year).
Earnings vs Industry: FFEA earnings growth over the past year (19.7%) exceeded the Pharmaceuticals industry -2.1%.
Return on Equity
High ROE: FFEA's Return on Equity (15.1%) is considered low.
Return on Assets
Return on Capital Employed
How is Faes Farma's financial position?
Financial Position Analysis
Short Term Liabilities: FFEA's short term assets (€211.4M) exceed its short term liabilities (€73.8M).
Long Term Liabilities: FFEA's short term assets (€211.4M) exceed its long term liabilities (€17.6M).
Debt to Equity History and Analysis
Debt Level: FFEA's debt to equity ratio (4%) is considered satisfactory.
Reducing Debt: FFEA's debt to equity ratio has reduced from 15.1% to 4% over the past 5 years.
Debt Coverage: FFEA's debt is well covered by operating cash flow (469.7%).
Interest Coverage: FFEA's interest payments on its debt are well covered by EBIT (302.6x coverage).
Inventory Level: FFEA has a high level of physical assets or inventory.
Debt Coverage by Assets: FFEA's debt is covered by short term assets (assets are 13.5x debt).
What is Faes Farma's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: FFEA's dividend (0.46%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.31%).
High Dividend: FFEA's dividend (0.46%) is low compared to the top 25% of dividend payers in the German market (3.63%).
Stability and Growth of Payments
Stable Dividend: FFEA is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: FFEA is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: FFEA is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FFEA's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Faes Farma has no CEO, or we have no data on them.
|Chairman of the Board of Directors||6.7yrs||€919.00k||0.41% €5.6m|
|Independent Director||12.7yrs||€66.00k||0.030% €398.3k|
|Independent Director||0yrs||€57.00k||no data|
|Independent Director||6.7yrs||€64.00k||0.32% €4.3m|
Experienced Board: FFEA's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.
Faes Farma, S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Faes Farma, S.A.
- Ticker: FFEA
- Exchange: DB
- Founded: 1933
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €1.343b
- Shares outstanding: 281.03m
- Website: https://faesfarma.com
Number of Employees
- Faes Farma, S.A.
- Parque empresarial "Cristalia" Calle Vía de los Poblados 3
- Edificio 2, 2º Izquierda (Hortaleza)
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FAE||BME (Bolsas y Mercados Espanoles)||Yes||Ordinary Shares||ES||EUR||Oct 1989|
|FFEA||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Oct 1989|
|0K9H||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Oct 1989|
|FAEE||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Oct 1989|
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Colme to treat chronic alcoholism; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. In addition, it offers sitagliptine, and sitagliptine and metformine products to treat diabetes type-II; Hidroferol; Acoxxel; Pankreoflat, an OTC products; Hemorrance for the treatment of haemorrhoids; and respiratory products, as well as ProFaes4 Adultos, Digest, Viajeros, Edad Escolar, and Dual Vit. Further, the company provides Diosmin and Micronized Diosmin for chronic venous insufficiency; Sulbutiamine to treat asthenia, concentration, and memory deficit; Arginine Aspartate for the treatment of erectile dysfunction; swine feeding and nutrition products; and products and services for the animal nutrition industry. It operates in approximately 60 countries in Latin America, Africa, the Middle East, Asia, and Europe. Faes Farma, S.A. was founded in 1933 and is headquartered in Madrid, Spain.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/22 21:49|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.